Macquarie Group
DNLI icon

Macquarie Group’s Denali Therapeutics DNLI Stock Holding History

Macquarie Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-832
Closed -$72K – 1921
2022
Q3 		$72K Sell
832
-579
-41% -$18.8K ﹤0.01% 1848
2022
Q2 		$42K Hold
1,411
– – ﹤0.01% 2095
2022
Q1 		$45 Sell
1,411
-40,750
-97% -$1.4M ﹤0.01% 2169
2021
Q4 		$1.88M Buy
42,161
+251
+0.6% +$11.9K ﹤0.01% 1390
2021
Q3 		$2.11M Hold
41,910
– – ﹤0.01% 1371
2021
Q2 		$3.29M Sell
41,910
-1,022
-2% -$63.2K ﹤0.01% 1257
2021
Q1 		$2.45M Buy
42,932
+8,091
+23% +$542K ﹤0.01% 1131
2020
Q4 		$2.92M Buy
34,841
+31,030
+814% +$1.88M ﹤0.01% 998
2020
Q3 		$137K Hold
3,811
– – ﹤0.01% 1702
2020
Q2 		$92K Buy
+3,811
New +$89.6K ﹤0.01% 1775

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return